These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24793951)

  • 21. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.
    Montplaisir J; Petit D; Quinn MJ; Ouakki M; Deceuninck G; Desautels A; Mignot E; De Wals P
    PLoS One; 2014; 9(9):e108489. PubMed ID: 25264897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective hospital-based case-control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009-2010 using matched hospital and test-negative controls.
    Hellenbrand W; Jorgensen P; Schweiger B; Falkenhorst G; Nachtnebel M; Greutélaers B; Traeder C; Wichmann O
    BMC Infect Dis; 2012 May; 12():127. PubMed ID: 22650369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.
    Roman F; Vaman T; Kafeja F; Hanon E; Van Damme P
    Clin Infect Dis; 2010 Sep; 51(6):668-77. PubMed ID: 20687838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns.
    Wijnans L; Lecomte C; de Vries C; Weibel D; Sammon C; Hviid A; Svanström H; Mølgaard-Nielsen D; Heijbel H; Dahlström LA; Hallgren J; Sparen P; Jennum P; Mosseveld M; Schuemie M; van der Maas N; Partinen M; Romio S; Trotta F; Santuccio C; Menna A; Plazzi G; Moghadam KK; Ferro S; Lammers GJ; Overeem S; Johansen K; Kramarz P; Bonhoeffer J; Sturkenboom MC
    Vaccine; 2013 Feb; 31(8):1246-54. PubMed ID: 23246544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season.
    Kawai AT; Li L; Kulldorff M; Vellozzi C; Weintraub E; Baxter R; Belongia EA; Daley MF; Jacobsen SJ; Naleway A; Nordin JD; Lee GM
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):548-53. PubMed ID: 24497128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial.
    Scheifele DW; Ward BJ; Dionne M; Vanderkooi OG; Loeb M; Coleman BL; Li Y;
    Vaccine; 2012 Jul; 30(32):4728-32. PubMed ID: 22652402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - Multi-country assessment.
    Weibel D; Sturkenboom M; Black S; de Ridder M; Dodd C; Bonhoeffer J; Vanrolleghem A; van der Maas N; Lammers GJ; Overeem S; Gentile A; Giglio N; Castellano V; Kwong JC; Murray BJ; Cauch-Dudek K; Juhasz D; Campitelli M; Datta AN; Kallweit U; Huang WT; Huang YS; Hsu CY; Chen HC; Giner-Soriano M; Morros R; Gaig C; Tió E; Perez-Vilar S; Diez-Domingo J; Puertas FJ; Svenson LW; Mahmud SM; Carleton B; Naus M; Arnheim-Dahlström L; Pedersen L; DeStefano F; Shimabukuro TT
    Vaccine; 2018 Oct; 36(41):6202-6211. PubMed ID: 30122647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvanted influenza a (H1N1) 2009 vaccine in patients with hematological diseases: good safety and immunogenicity even in chemotherapy-treated patients.
    Cherif H; Höglund M; Pauksens K
    Eur J Haematol; 2013 May; 90(5):413-9. PubMed ID: 23444982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea.
    Song JY; Cheong HJ; Heo JY; Noh JY; Choi WS; Park DW; Lee J; Jeong HW; Kee SY; Kim WJ
    Vaccine; 2011 Feb; 29(7):1395-8. PubMed ID: 21199701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.
    De Serres G; Rouleau I; Skowronski DM; Ouakki M; Lacroix K; Bédard F; Toth E; Landry M; Dupré N
    Vaccine; 2015 Aug; 33(36):4464-71. PubMed ID: 26209839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.
    Zuccotti GV; Pariani E; Scaramuzza A; Santoro L; Giani E; Macedoni M; Gazzarri A; Anselmi G; Amendola A; Zanetti A
    Diabet Med; 2011 Dec; 28(12):1530-6. PubMed ID: 21916971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of adverse events following immunization with pandemic influenza A (H1N1)pdm09 vaccine with or without adjuvant among health professionals in Rio de Janeiro, Brazil.
    Cerbino-Neto J; Santos AT; Gouvea MI; Pedro RS; Ramos GV; Guaraldo L; Werneck GL
    Mem Inst Oswaldo Cruz; 2012 Nov; 107(7):923-7. PubMed ID: 23147150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monovalent H1N1 influenza vaccine safety in pregnant women, risks for acute adverse events.
    Nordin JD; Kharbanda EO; Vazquez-Benitez G; Lipkind H; Lee GM; Naleway AL
    Vaccine; 2014 Sep; 32(39):4985-92. PubMed ID: 25045808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years.
    Saitoh A; Nagai A; Tenjinbaru K; Li P; Vaughn DW; Roman F; Kato T
    Hum Vaccin Immunother; 2012 Jun; 8(6):749-58. PubMed ID: 22495117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic.
    Engelhard D; Zakay-Rones Z; Shapira MY; Resnick I; Averbuch D; Grisariu S; Dray L; Djian E; Strauss-Liviatan N; Grotto I; Wolf DG; Or R
    Vaccine; 2011 Feb; 29(9):1777-82. PubMed ID: 21216315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
    Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
    Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
    Palma P; Romiti ML; Bernardi S; Pontrelli G; Mora N; Santilli V; Tchidjou HK; Aquilani A; Cotugno N; Alghisi F; Lucidi V; Rossi P; Douagi I
    Biologicals; 2012 Mar; 40(2):134-9. PubMed ID: 22261282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.